Treatment of idiopathic pulmonary fibrosis (IPF) with Esbriet (pirfenidone) increased five-year survival, and also resulted in less decline in lung function at two years, according to a real-life study from the Czech Republic. The findings also revealed that a specific measure of lung function called diffusing lung capacity…
He’s a musician and a clothing designer. He’s a published author. He’s a professional scuba-diving instructor — and he has an intense passion for underwater shark photography. In fact, Noah Greenspan is anything but your typical New York pulmonary physical therapist. Since 1998, Greenspan has been running the Pulmonary Wellness…
A protein called cadherin-11 (CDH11) ties together macrophages and myofibroblasts in an “eternal hug” in the lungs of idiopathic pulmonary fibrosis (IPF) patients, promoting a profibrotic environment, a study shows. Therapies that target CDH11 and break the “hug” between the two cell types may help stop this profibrotic process. The…
A large, multi-center clinical trial testing the proton pump inhibitor omeprazole as a therapy for cough in idiopathic pulmonary fibrosis (IPF) patients seems achievable and justified, according to results of a single-center pilot trial. The pilot study also suggests the need to screen large patient numbers and monitor adverse side…
The tolerability and safety of Ofev (nintedanib) and Esbriet (pirfenidone) treatments in a small group of patients with idiopathic pulmonary fibrosis (IPF) in South England were found to be similar to real-world data. The research confirmed the safety of both IPF therapies. The retrospective study, “South-West…
Synairgen announced it successfully completed three-month toxicity studies on LOXL2 (lysyl oxidase like 2) inhibitor candidates for treating idiopathic pulmonary fibrosis (IPF). The LOXL2 program, developed in collaboration with Pharmaxis, may move into Phase 2 trials. Synairgen and Pharmaxis began their collaboration in 2015 to develop…
Bridge Biotherapeutics’ investigational therapy candidate BBT-877 for idiopathic pulmonary fibrosis (IPF) has been awarded orphan drug designation by the U.S. Food and Drug Administration (FDA). According to the company, BBT-877 is a best-in-class autotaxin (ATX) inhibitor, and a potential anti-inflammatory and anti-fibrotic treatment for IPF. Studies have shown…
Blocking the platelet-derived growth factor receptor-beta (PDGFR-β) prevents lung fibrosis in a mice model of pulmonary fibrosis, a study says. Based on these observations, scientists believe that PDGFR-β blockade may someday be a viable therapeutic option for patients with idiopathic pulmonary fibrosis (IPF). The findings of the study, “Blockade…
A new subtype of immune cells carrying a unique genetic profile was identified and found to have an important role in the progression of fibrosis in the lungs, a study reports. The study, “Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage,” was published in…
A small Phase 1 pilot study found improved physical function in idiopathic pulmonary fibrosis (IPF) patients treated with senolytic therapies. The trial was conducted by researchers at University of Texas Health San Antonio, in collaboration with the Mayo Clinic and the Wake Forest School of Medicine. The findings…
Get regular updates to your inbox.
